Shanghai Ark Biopharmaceutical Co., Ltd announced today that China’s National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for AK0406 injection, the company’s first antiviral drug-Fc conjugate (AFC) candidate designed for long-acting influenza prevention. The approval makes AK0406 the first influenza-focused AFC candidate in China to progress into clinical development.

AK0406 is a next-generation, long-acting antiviral candidate discovered and developed by ArkBio. The molecule combines a highly potent antiviral small-molecule agent with an antibody Fc fragment through targeted conjugation, with the aim of delivering sustained protection before and after exposure and potentially offering therapeutic benefits.

This approach is intended to address the continuing need for effective influenza prevention, particularly during periods of high seasonal transmission. Preclinical studies indicate that AK0406 has potent and broad activity against both influenza A and influenza B viruses, while retaining immune effector activity and achieving prolonged systemic exposure. Its molecular design is intended to provide a balanced profile suitable for both influenza prophylaxis and treatment.

ArkBio is also advancing AK0406 through international clinical development. In February 2026, the company received authorization from an Australian Human Research Ethics Committee (HREC) to begin a Phase I study. Recruitment and dosing of healthy adult participants across all planned cohorts in Australia have been completed, and the study has subsequently moved into the follow-up stage.

Influenza continues to represent a substantial global public health burden. Existing prevention strategies rely heavily on seasonal vaccination, but these approaches have inherent challenges. These include the difficulty of accurately anticipating and matching circulating viral strains each year, the effects of ongoing antigenic drift, and lower levels of vaccine protection in certain vulnerable groups, including older adults and people with compromised immune systems. Consequently, significant unmet needs remain in influenza prevention.

ArkBio plans to work closely with China’s Center for Drug Evaluation (CDE) to support the continued clinical development of AK0406 in China while completing follow-up activities associated with the Phase I study in Australia. Through a coordinated development strategy spanning China and international markets, the company intends to advance the program efficiently and ultimately develop a safe, effective, and convenient option for influenza prevention worldwide.

Vimgreen Pharmaceuticals, a prominent company focused on modulating adenosine signaling pathways, has announced that China’s Center for Drug Evaluation (CDE) has cleared its Investigational New Drug (IND) application for VG081821 in non-alcoholic steatohepatitis (NASH), now more commonly termed metabolic dysfunction-associated steatohepatitis (MASH). This milestone marks the second clinical application for the company’s lead candidate, which is already being developed for Parkinson’s disease.

The approval represents the first worldwide authorization to study an A2A receptor antagonist in NASH. With this clearance, VG081821 can move directly into Phase II trials for NASH, accelerating its clinical development timeline as a potential novel therapy.

NASH is a chronic liver condition marked by fat buildup (steatosis), liver cell damage, inflammation, and progressive scarring (fibrosis). As obesity and metabolic disorders continue to rise globally, NASH has become a major contributor to cirrhosis and liver cancer. Despite its growing impact, treatment options remain scarce, with only two drugs—resmetirom and semaglutide—receiving accelerated approvals so far, highlighting a significant unmet medical need.

VG081821 works as an A2A receptor antagonist, targeting the three key drivers of NASH: fat accumulation, inflammation, and fibrosis. This broad mechanism of action is particularly advantageous given the disease’s complex biology, positioning the drug as a strong therapeutic contender.

Epidemiological research further supports this approach. Several large studies have linked moderate coffee consumption with a reduced risk of chronic liver disease. Caffeine, the primary active compound in coffee, provides liver-protective effects largely by inhibiting A2A receptors. VG081821, being more potent and selective than caffeine, is designed to enhance these benefits with greater precision.

What sets VG081821 apart from conventional A2A receptor blockers like istradefylline is its unique pharmacological behavior. While standard antagonists simply prevent receptor activation, VG081821 functions as an inverse agonist—reducing both stimulated and baseline receptor activity. This dual action may result in more comprehensive suppression of harmful signaling pathways and improved therapeutic outcomes.

The drug is also being developed for Parkinson’s disease, where it aims to address both symptoms and underlying disease processes. In Phase II studies involving patients with early to mid-stage Parkinson’s, VG081821 showed meaningful improvements in motor function and met key efficacy targets, indicating strong potential as a standalone treatment. The main side effect observed was a temporary rise in liver transaminases, likely due to metabolic changes in the liver rather than toxicity. Similar transient effects have been noted with other lipid-modulating therapies and are generally considered harmless adaptive responses.

Sanxing Sun, President and CEO of Vimgreen Pharmaceuticals, expressed enthusiasm about the progress, noting that VG081821’s mechanism differs significantly from existing THR-beta agonists and GLP-1–based treatments. By enhancing hepatic lipid processing while reducing inflammation and fibrosis, the therapy is well-positioned to address critical gaps in metabolic liver disease treatment and improve patient outcomes.

The company plans to begin a Phase IIa clinical trial for NASH in the latter half of the year.